Carl Zeiss Meditec AG
XETRA:AFX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
45.8
121.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG
Accounts Payable
Carl Zeiss Meditec AG
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Carl Zeiss Meditec AG
XETRA:AFX
|
Accounts Payable
€186.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
Stratec SE
XETRA:SBS
|
Accounts Payable
€13.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
8%
|
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
Accounts Payable
€6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
3%
|
|
|
Siemens Healthineers AG
XETRA:SHL
|
Accounts Payable
€2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Draegerwerk AG & Co KGaA
XETRA:DRW8
|
Accounts Payable
€198.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Sartorius AG
XETRA:SRT
|
Accounts Payable
€226.3m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
Carl Zeiss Meditec AG
Glance View
Carl Zeiss Meditec AG stands as a beacon in the realm of medical technology, carving a niche through its innovative solutions in ophthalmology and microsurgery. Rooted in the prestigious legacy of the Zeiss Group, this company seamlessly fuses cutting-edge technology with practical medical applications. Its headquarters in Jena, Germany, serve as the crucible for pioneering research and development endeavors, channeling expertise into products that enhance both diagnostic and surgical capabilities. The heart of its operations revolves around creating technological marvels such as optical coherence tomography (OCT) instruments and surgical microscopes, which bring precision and enhanced clarity to the medical field. Through a well-executed blend of R&D and strategic acquisitions, Carl Zeiss Meditec consistently remains at the forefront of medical innovation, ensuring it meets the ever-evolving needs of the healthcare sector. Financially, the company thrives by selling its sophisticated medical devices directly to healthcare professionals, hospitals, and clinics worldwide. Rather than merely creating instruments, Carl Zeiss Meditec's business model is deeply entwined with providing comprehensive workflow solutions and service support, ensuring that medical practitioners extract maximum utility from their investments. By offering not just products but also extensive after-sales service and maintenance, the company builds sustained relationships with its clients, fostering a cycle of trust and repeat business. In addition, its engagement in training and support services enhances user competencies, ensuring the seamless integration of its technology into everyday medical practice and underscoring its commitment to elevating healthcare standards globally. Through this multifaceted approach, Carl Zeiss Meditec solidifies its position as an indispensable ally in the medical community, both as a supplier of state-of-the-art equipment and as a provider of essential healthcare solutions.
See Also
What is Carl Zeiss Meditec AG's Accounts Payable?
Accounts Payable
186.7m
EUR
Based on the financial report for Jun 30, 2024, Carl Zeiss Meditec AG's Accounts Payable amounts to 186.7m EUR.
What is Carl Zeiss Meditec AG's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
16%
Over the last year, the Accounts Payable growth was -3%. The average annual Accounts Payable growth rates for Carl Zeiss Meditec AG have been 15% over the past three years , 12% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet